They mention that it reduces discomfort that accompanies IBS and diverticulitis, and that it doesn't bung you up and naturally leaves your body.

Subjects randomised to the experimental group received Enterosgel (n=51) to be taken according to instructions dependent on stool frequency and consistency and standard care, that is, oral rehydration solution (ORS) for 6–8 days. It may be that some knew which treatment they had taken (became unblinded) once they started the open-label phase when all patients took Enterosgel.You can change your choices at any time by visiting Cookie preferences, as described in the Cookie notice. The visit will involve confirmation of eligibility, informed consent and assessment of symptoms and relevant disease history. Professor Yan Yiannakou, Department of gastroenterology, County Durham and Darlington NHS Foundation Trust, Darlington, Darlington, UK; yan. What happened during the study: 440 patients were recruited and given either Enterosgel or placebo, which they took for 8 weeks (Double-blind phase). Here you can watch the webinar where study patients were the first people to learn about the results and were able to ask questions to the lead clinician on the study.

In case of long term diarrhoea you should consult a doctor to obtain diagnosis of the underlying condition. A total of 20 subjects had a pathogen detected (7 Enterosgel and 13 control), the HR for the primary outcome was 1. Furthermore, none of the patients had an unscheduled visit to their General Practitioner (GP) where the reason for visit was an AE related to intestinal infection. Thus, Enterosgel may have an additional benefit, especially in vulnerable groups; for example, children and elderly or immunocompromised/renal dialysis/receiving chemotherapy where more rapid resolution of diarrhoeal symptoms could have a beneficial impact on health.

Ten primary care practices participated to recruit 105 subjects, randomised in 1:1 ratio into two treatment arms for an 8-day treatment phase. Division of Diabetes, Endocrinology and Gastroenterology, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK. Inclusion criteria included aged 18–70 years with a patient-reported episode of acute diarrhoea, defined as at least three watery stools within the last 48 hours. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. As these patients were mainly from the working population, the indirect benefit from this rapid resolution of symptoms could translate to prevention of further complications, less healthcare visits with reduced absence from work and a reduction in the economic burden on society.

Irritable Bowel Syndrome (IBS) is a common condition causing around 1 in 10 people to seek help from their GP at some point in their lives. A remedy for inhibiting the growth of staphylococci, suppressing the staphylococcal enterotoxins production and removing them from biological substrates. Patients should not change their treatment based on the results of this study without first talking to their doctor or healthcare professional.Prospective studies have shown that up to 36% of intestinal infections can be followed by prolonged post-infective irritable bowel syndrome. If you want to download trial data, please consult the FAQs page where the section "Finding trial information" includes details about the XML API. This site uses session cookies and persistent cookies to improve the content and structure of the site.

Randomisation was completed using a computer-based stratified permuted blocks randomisation tool in the electronic case report form (Sealed Envelope Ltd, London, UK). The study will also investigate the impact of Enterosgel® on the quality of life, work productivity and activity and general health, and evaluate whether Enterosgel® has long-term effects.

ENTEROSGEL® is not absorbed by the body and is expelled with the stool, this way eliminating the adsorbed toxins and harmful substances, which can be beneficial for the treatment of acute diarrhoea and IBS-D. A subgroup analysis was conducted in subjects whose stool samples were positive for an infectious agent. This randomised controlled multicentre trial aimed to investigate its safety and efficacy in patients with IBS-D. Results 440 patients with IBS-D were randomised to the double-blind phase with 393 continuing to the open-label phase.